Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Horizon Therapeutics PLC

www.horizonpharma.com

Latest From Horizon Therapeutics PLC

US Appeals Court Refuses To Review Pennsaid 2%

Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.

Legal Issues Generic Drugs

Hypera Pays $825m For Takeda LatAm Portfolio

Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.

South America Business Strategies

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Approvals Drug Review

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

UsernamePublicRestriction

Register